HISTIDINE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 155.0 | -0.6 | 3 | 3 | 92.0 | 3 | 0.33 |
- CAS
- 71001
- UNII
- 4QD397987E
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 101 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00811785 | 2008-12-01 | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Phase 3 | Recruiting |
| NCT00001262 | 1990-06-01 | Copper Histidine Therapy for Menkes Diseases | Phase 2 | Completed |
(Browse) Purchasable Analogs in ZINC
Functions of Histidine
| Ds - Dietary supplement |
| Nutr - Nutrient |
Regulatory Status of Histidine
| Reg - Food additives for which a petition has been filed and a regulation issued. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Intravenous | Injection, Suspension, Liposomal | 0.16% |
| Iv(Infusion) | Injection | 37.2% |
| Iv(Infusion) | Injection, Liposomal | 0.02% |
| Iv(Infusion) | Solution, Injection | 0.09% |
| Oral | Suspension | 0.5% |
| Subcutaneous | Powder, For Injection Solution, Lyophilized | 0.39% |
| Subcutaneous | Solution, Injection | 0.07% |